LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine.

@article{Sang2004LY293558AN,
  title={LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine.},
  author={Christine N. Sang and Nabih M. Ramadan and Rebecca Wallihan and Amy S. Chappell and Frederick G. Freitag and Timothy R. S. Smith and Stephen David Silberstein and Kirk W. Johnson and Lee Phebus and David Bleakman and Paul L Ornstein and Bernhard Arnold and Stewart J. Tepper and Francois R. Vandenhende},
  journal={Cephalalgia : an international journal of headache},
  year={2004},
  volume={24 7},
  pages={596-602}
}
Glutamatergic hyperactivity is implicated migraine pathogenesis. Also, LY293558, an alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainate (KA) receptor antagonist, is effective in preclinical models of migraine. We therefore tested LY293558 in acute migraine. We conducted a randomized, triple-blind, parallel-group, double-dummy, multicentre trial of 1.2 mg/kg intravenous (IV) LY293558, 6 mg subcutaneous (SC) sumatriptan, or placebo in the treatment of acute migraine. The… CONTINUE READING